The Effect of Mavacamten on Echocardiographic Parameters, Cardiac Function and Biomarkers in Hypertrophic Cardiomyopathy Patients, A Systematic Review and Meta-Analysis.

Background: Evaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).

Methods: We searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95% confidence intervals (CI).

Results: Seven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95% CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95% CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95% CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.

Conclusions: Mavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.